Zotarolimus vs Sirolimus Eluting Stent in High Bleeding Risk
A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 280 participants.
Also called NCT05240781
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 280 participants
- Registry
-
NCT05240781
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Mexico
- Registry status
- Unknown status
Technical summary
Registry record NCT05240781. Randomized; double masking; primary purpose treatment. Start 2021-09-29 (actual); primary completion 2024-02-28 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Zotarolimus vs Sirolimus Eluting Stent in High Bleeding Risk
- Acronym
- ZEVS-HBR
- Condition
- High Bleeding Risk
- Condition
- Coronary Artery Disease
- Condition
- Percutaneous Coronary Intervention
- Intervention (Device)
- Zotarolimus eluting stent
- Intervention (Device)
- Sirolimus eluting stent
- Lead sponsor
- Instituto Nacional de Cardiologia Ignacio Chavez
Record details
- Record id
cardio:ct-nct05240781- Content hash
a608a22d0df4b6d511ac4bbec7dd0400e7c65b45c025a9ff9c28ba738cdb82fe